Novartis’ Cosentyx could be heading for a fourth indication after the company published late-stage trial data showing it improved symptoms in patients with non-radiographic axial spondyloar
Eli Lilly is hoping new data from its Taltz (ixekizumab) could give it another potentially lucrative indication and put pressure on Novartis’ rival IL-17a drug, Cosentyx.
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS